Hims & Hers trims 2026 revenue forecast: Can HIMS fall further?

Traders Union
All News
Stocks
Hims & Hers falls 11.75% to $22.94

Highlights

Hims & Hers Health reported Q3 2026 revenue of $890.4 million, up 49% year over year, yet posted an unexpected quarterly loss.
Gross margin fell to 57% from 74% and full-year revenue guidance dropped to $3.13 billion to $3.15 billion.
Shares of Hims & Hers stock declined 11.75% to $22.94, with technical indicators showing strong bearish momentum and high downside probability within a $20.35 to $25.53 range.

Profitability and outlook fall amid rising costs and drug shift

Hims & Hers Health reported a 49% year-over-year increase in Q3 2026 revenue to $890.4 million, yet a sharp decline in gross margin to 57% from 74% a year ago resulted in an unexpected quarterly loss and a reduction in full-year core profit guidance to $257 million–$277 million, according to 247wallst. This deterioration in profitability and earnings visibility weighed heavily on market sentiment, especially as the company also lowered its full-year revenue outlook to $3.13 billion–$3.15 billion, a figure that fell short of previously anticipated levels, as noted by Yahoo Finance. The shift from compounded GLP-1 medications to FDA-approved branded weight-loss drugs further increased costs and contributed to margin pressure, with these changes following collaborations with pharmaceutical partners, according to 247wallst.

Bearish momentum persists as price holds under major technical levels

On the technical front, HIMS/USD trades below the MA-20 and MA-50 on the hourly chart, and remains under the MA-200 on the daily timeframe. The Ichimoku Kijun at $25.31 now acts as immediate resistance. Momentum indicators highlight ongoing weakness: both MACD and ADX reflect a bearish bias, while RSI and CCI are neutral. Stoch RSI is in oversold territory, indicating possible short-term exhaustion in selling. Bull/Bear Power remains negative, and the Awesome Oscillator confirms this prevailing bearish tone.

Near-term downside risk dominates amid range-bound price action

In the short term, the price is expected to fluctuate within a range of $20.35 to $25.53, in line with recent high volatility. The probability of a reversal to the upside is considered very low, with sellers likely to remain in control. Key scenarios include a baseline consolidation between support and resistance, limited upside potential in case of a break above $25.31, and further downside risk if the price falls below $20.35.

Anton Kharitonov, expert at Traders Union, believes Hims & Hers Health is pressured by fundamental setbacks and confirming technical weakness. Earnings miss, sharp margin contraction, and cautious guidance have undermined sentiment and reinforced the prevailing bearish trend. Key levels at $25.31 and $20.35 frame any tactical scenario, but there is little to support a recovery while profitability remains under pressure. "As long as price stays below $25.31, I remain skeptical and see no tactical reason to buy."

Earlier, analysts noted that Hims & Hers faced persistent downside momentum and technical weakness, despite potential long-term catalysts from new pharmaceutical partnerships. The latest earnings-related selloff and reduction in full-year guidance reinforce this bearish outlook, with further downside risk if the stock breaks below the $20.35 support level.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.